Ascenta reports positive preliminary results from Phase II cancer trial
Initial findings from the ongoing open-label, multi-center study demonstrates that AT-101 can be administered safely with docetaxel and prednisone (D/P) in these patients. Investigators also observed clinical responses,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.